$ News

Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple

Oppenheimer Downgrades Ventyx Biosciences to Perform

HC Wainwright & Co. Downgrades Ventyx Biosciences to Neutral, Announces $14 Price Target

UBS Downgrades Ventyx Biosciences to Neutral, Lowers Price Target to $14

LifeSci Capital Downgrades Ventyx Biosciences to Market Perform, Announces $14 Price Target

Canaccord Genuity Downgrades Ventyx Biosciences to Hold, Lowers Price Target to $14

Lilly To Acquire Ventyx Biosciences For $14.00/Share In All-Cash Deal Valued At ~$1.2B

UBS Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $20

Eli Lilly (LLY) Stock Is Up, What You Need To Know

Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell

Ventyx Biosciences shares are trading higher after a WSJ report indicating Eli Lilly is nearing a $14 per share deal to acquire the company.

Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition

Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billion

Trending tickers: Micron, Sandisk Corporation, Ventyx Biosciences, BP and Reckitt

UPDATE: 'Eli Lilly Nears Deal for Biotech Ventyx'; "Companies Are Discussing A Deal In Which Eli Lilly Would Pay $14/Share In Cash For Ventyx" - WSJ

Stocks to Watch Wednesday: Strategy, Applied Digital, Chevron

Ventyx Biosciences shares are trading higher after a WSJ report indicating Eli Lilly is nearing a deal to acquire the company.

'Eli Lilly Nears Deal for Biotech Ventyx' - WSJ

One Ventyx Biosciences Insider Raised Their Stake In The Previous Year

Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives